stock · yahoo

Abbott Laboratories

ABT

$100.68
1.85 (1.87%)
polled · warming up

Below: live stock price for Abbott Laboratories (ABT), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

Abbott Laboratories (ABT) is a Healthcare company based in United States. Operating in Medical Devices, it employs about 122,000 people. Over the past year ABT traded between 81.97 and 137.49 USD. Trailing P/E sits near 28.2 on a market cap of about 175.37B USD. It currently yields 2.50% in dividends.

Day
+1.87%
+1.85
Week
+7.19%
+6.75
Month
+13.88%
+12.27
Year
Prev close
$98.83
Volume (24h)
$1.72B
Market cap
$175.37B
Currency
USD

Score

49/ 100 · Mixed

Coverage: 6/7
  • Value52
  • Quality74
  • Momentum21
  • Growth24
  • Risk79
  • Dividend42
  • Liquidity

Composite of public market data. Informational only — not investment advice.

Trend projection

Where the recent trend points if it continues.

UptrendFit 27%Pace +0.12% per bar
+5 bars+20 bars+60 bars+120 bars
+5 bars
101.1581
+0.47%
Bull118.4078
Bear86.4214
+20 bars
101.8216
+1.13%
Bull139.508
Bear74.3157
+60 bars
102.0795
+1.39%
Bull176.1214
Bear59.1649
+120 bars
102.0889
+1.40%
Bull220.7846
Bear47.205

Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0352 USD.

Interpretation

Composite signals look mixed. Strength: risk profile with weakness: momentum. Price sits near the upper third of the recent range, trend is sloping upward.

Descriptive observation — not investment advice.

Score breakdown

Raw values behind each pillar so you can see what the composite is reading.

  • Value
    52/100

    Value looks mixed — driven by P/E (28.2).

    P/E:28.2P/B:3.37PEG:1.5
  • Quality
    74/100

    Quality looks solid — driven by Gross margin (56.77%).

    Profit margin:11.65%Gross margin:56.77%
  • Momentum
    21/100

    Momentum looks fragile — driven by 52w change (-19.08%).

    52w change:-19.08%
  • Growth
    24/100

    Growth looks fragile — driven by Earnings growth (-47.50%).

    Revenue growth:13.00%Earnings growth:-47.50%
  • Risk
    79/100

    Risk looks strong — driven by Debt / equity (64.77).

    Beta:0.61Debt / equity:64.77Short interest:1.50%
  • Dividend
    42/100

    Dividend looks weak — driven by Payout ratio (67.23%).

    Dividend yield:2.50%Payout ratio:67.23%

Derived from public market data — informational, not investment advice.

Reference levels

Fibonacci retracements and extensions across the recent range.

60 bars

Reference only — not investment advice.

These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.

  • ResistanceFib +161.8% extension
    134.7489 USD
    +33.84% from current
  • ResistanceFib +100% extension
    122.29 USD
    +21.46% from current
  • ResistanceFib +61.8% extension
    114.5889 USD
    +13.81% from current
  • ResistanceFib +27.2% extension
    107.6135 USD
    +6.89% from current
  • Current
    100.68 USD
  • SupportFib 23.6% retracement
    97.3722 USD
    -3.29% from current
  • SupportFib 38.2% retracement
    94.4289 USD
    -6.21% from current
  • SupportFib 50% midpoint
    92.05 USD
    -8.57% from current
  • SupportFib 61.8% retracement
    89.6711 USD
    -10.93% from current
  • SupportFib 78.6% retracement
    86.2842 USD
    -14.30% from current
  • SupportFib −27.2% extension
    76.4865 USD
    -24.03% from current
  • SupportFib −61.8% extension
    69.5111 USD
    -30.96% from current
  • SupportFib −100% extension
    61.81 USD
    -38.61% from current

Financials

52w high
$137.49
52w low
$81.97
52w change
-19.08%
Day high
$102.13
Day low
$99.47
P/E (TTM)
28.2
Forward P/E
16.6
PEG
1.5
Price / Book
3.37
Beta (5Y)
0.61
Enterprise value
202.85B
EV / Revenue
4.35
EV / EBITDA
17.09
EPS (TTM)
$3.57
Forward EPS
$6.07
Dividend yield
2.50%
Dividend rate
$2.52
Payout ratio
67.23%
Revenue (TTM)
46.58B
EBITDA
11.87B
Total cash
7.3B
Total debt
34.14B
Debt / Equity
64.77
Profit margin
11.65%
Gross margin
56.77%
Shares outstanding
1.74B
Float
1.73B
Sector: HealthcareIndustry: Medical DevicesHQ: United StatesEmployees: 122Kwww.abbott.com

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Analyst & Risk

Consensus
Buy
Mean rating1.67 / 5
Analysts24
Next earnings2026-10-14
Strong buy 4Buy 16Hold 7
Analyst price target
$118.33
Mean target · 24 analysts
+17.5%
upside
Low $92.00Now $100.68High $135.00
Beta (vs S&P 500)
0.61
less volatile
52-week change
-19.08%
Short % of float
1.50%
Short ratio (days)
1.67
Debt / Equity
64.77
very high leverage
PEG ratio
1.5
fair
EV / Revenue
4.35
EV / EBITDA
17.09
Revenue growth
13.00%
Earnings growth
-47.50%
EBITDA
11.87B
Total cash
7.3B
Total debt
34.14B
Insider holdings
0.49%
Institutional
82.43%

Recent rating changes

  • 2026-07-17CitigroupBuyBuymain
  • 2026-07-17Piper SandlerOverweightOverweightreit
  • 2026-07-17JP MorganOverweightOverweightmain
  • 2026-07-17Wells FargoOverweightOverweightmain
  • 2026-07-17TD CowenBuyBuyreit
  • 2026-07-17Evercore ISI GroupOutperformOutperformmain
  • 2026-07-17RBC CapitalOutperformOutperformreit
  • 2026-07-17BTIGBuyBuymain

Recent news

Related

Other assets in this category.

Live discussion

Sign in to join the discussion.

  • No comments yet. Be the first.